Australian Broker Call

Macquarie rates A4N as No Rating (-1) -

Macquarie observes 98% of shares have voted in favour of the issuance of a second tranche of placement, equating to an additional 160m Alpha HPA shares raising $120m.

This will complete the funding and has seen the share price decline by -22% over the past month as the market absorbs the equity issuance for the Stage 2 project.

The analyst has lifted its basket price forecast to US$27/kg by FY31 as semiconductor demand strengthens.

FY26 earnings forecasts are lifted by 7% on lower expected stage 1 losses, minor adjustments for FY27, and FY28-30 forecasts trimmed by 3-5%, reflecting slightly lower operating earnings and higher interest costs from royalties.

The broker is on research restriction, so no target price or rating.

Current Price is $0.55. Target price not assessed.

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates AAI as Neutral (3) -

UBS is more constructive on aluminium and cautious on alumina following Middle East conflict related logistics disruptions, which could threaten around 10% of global smelting capacity in the Gulf and lift aluminium premiums in the US and Europe.

The broker expects disruptions to reduce alumina demand while tightening aluminium markets, creating favourable relative pricing for aluminium producers such as Alcoa.

Higher gas prices following the conflict are also supporting thermal coal prices in the near term, though UBS still expects thermal coal demand to decline over the medium term with prices trending back below US$100/t.

Metallurgical coal prices are expected to remain supported above US$200/t near term due to weather risks and Indian demand growth, with UBS forecasting about US$220/t in 2027. 

Target price on Alcoa is raised to $95 from $71 with a Neutral rating retained.

Target price is $95.00 Current Price is $86.73 Difference: $8.27
If AAI meets the UBS target it will return approximately 10% (excluding dividends, fees and charges).

The company's fiscal year ends in December.

Forecast for FY25:

Forecast for FY26:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.5

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates BRE as Buy (1) -

Ord Minnett highlights Brazilian Rare Earths’ Sulista rare earth project update shows mineralisation strike length expanding to 17km from 10km following new exploration surveys

Multiple walk-up drill targets and early drilling across Sulista East are noted, with grades around 2-5% total rare earth oxides (TREO) versus 13-16% at Monte Alto.

The broker points out Sulista forms part of the Rocha da Rocha province, hosting high-grade rare earth mineralisation alongside around 86mt bauxite potentially suitable for direct export.

Speculative Buy rating and $7.50 target are kept.

Target price is $7.50 Current Price is $5.63 Difference: $1.87
If BRE meets the Ord Minnett target it will return approximately 33% (excluding dividends, fees and charges).

The company's fiscal year ends in December.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates BXB as Neutral (3) -

UBS expects Brambles’ sales growth to track toward the lower end of FY26 guidance as soft FMCG volumes and weak like for like pallet demand offset modest restocking and new business wins.

Nielsen data indicates US food and household product volumes remain negative y/y, while CHEP volumes were flat in 1H26 as contract gains offset weaker underlying demand.

The analyst forecasts FY26 constant currency revenue growth of around 3%, assuming like for like volumes recover in 2H26 supported by easier comparables and US World Cup related activity.

Neutral rating and $25.40 target unchanged.

Target price is $25.40 Current Price is $22.61 Difference: $2.79
If BXB meets the UBS target it will return approximately 12% (excluding dividends, fees and charges).

Current consensus price target is $26.79, suggesting upside of 19.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates CKF as Buy (1) -

Collins Foods’ acquisition of eight KFC restaurants in Bavaria expands its German footprint, Citi notes, offering an entry into another state and supporting a faster European network rollout.

The broker views the transaction as strategically positive despite limited near-term earnings contribution, given potential for longer-term store expansion.

Separately, management's trading update indicates to the broker improving momentum in Germany, with same-store sales rising to 5.1% over the past 14 weeks from 2.3% earlier in the second half.

It's felt this improvement indicates strong operational execution in Germany and aligns with recent industry trends reported by AmRest.

Australia same-store sales softened slightly to 3.1% over the past 14 weeks from 3.6% earlier in the period.

FY26 profit guidance was reiterated for mid-to-high teens growth, broadly consistent with consensus expectations.

Buy rating and $12.85 target price retained.

Target price is $12.85 Current Price is $9.43 Difference: $3.42
If CKF meets the Citi target it will return approximately 36% (excluding dividends, fees and charges).

Current consensus price target is $12.06, suggesting upside of 21.2% (ex-dividends)

The company's fiscal year ends in April.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates CRN as Downgrade to Neutral from Buy (3) -

UBS is more constructive on aluminium and cautious on alumina following Middle East conflict related logistics disruptions, which could threaten around 10% of global smelting capacity in the Gulf and lift aluminium premiums in the US and Europe.

The broker expects disruptions to reduce alumina demand while tightening aluminium markets, creating favourable relative pricing for aluminium producers such as Alcoa.

Higher gas prices following the conflict are also supporting thermal coal prices in the near term, though UBS still expects thermal coal demand to decline over the medium term with prices trending back below US$100/t.

Metallurgical coal prices are expected to remain supported above US$200/t near term due to weather risks and Indian demand growth, with the analyst forecasting about US$220/t in 2027.

Coronado Global Resources is downgraded to Neutral from Buy. Target price lifts to 40c from 46c.

Target price is $0.40 Current Price is $0.36 Difference: $0.04
If CRN meets the UBS target it will return approximately 11% (excluding dividends, fees and charges).

Current consensus price target is $0.41, suggesting upside of 17.9% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY26:

Forecast for FY27:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates FCL as Buy (1) -

Fineos Corporation’s FY25 result on February 25 featured stronger-than-expected revenue guidance despite currency headwinds, Citi recaps, with growth forecast to accelerate to around 8% in FY26.

The broker highlights stronger conversion from annual recurring revenue (ARR) into subscription revenue, supported by existing clients expanding usage across the platform.

Policy and Billing remains a key opportunity, the analysts add, as the full AdminSuite cloud release should support cross-selling to existing North American insurers.

The FY26 earnings (EBITDA) forecast is increased by 5% with potential upside flagged to FY27 estimates if subscription revenue reaches 65% of group revenue.

Buy. Target $3.25.

Target price is $3.25 Current Price is $2.46 Difference: $0.79
If FCL meets the Citi target it will return approximately 32% (excluding dividends, fees and charges).

This company reports in EUR. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates GMG as Buy (1) -

Australian real estate fundamentals remain strong following the February reporting season, Citi suggests, with retail, residential, self-storage, data centres and industrial assets showing solid operating momentum.

The broker highlights cap rates continue to compress, supporting higher asset valuations and stronger balance sheets across the sector.

Leasing spreads are considered favourable reflecting strong landlord negotiating power and resilient tenant demand.

Citi sees improving capital flows and potential asset value gains over the next 12-18 months, though higher bond yields and domestic inflation remain key near-term risks.

The $40 target and Buy rating for Goodman Group are unchanged.

Target price is $40.00 Current Price is $27.07 Difference: $12.93
If GMG meets the Citi target it will return approximately 48% (excluding dividends, fees and charges).

Current consensus price target is $36.05, suggesting upside of 37.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates GQG as Upgrade to Buy from Accumulate (1) -

Morgans raises its target price for GQG Partners to $2.03 from $1.89 and upgrades to Buy from Accumulate due to an improved investment performance.

The February funds under management (FUM) update revealed FUM rising 4.3% month-on-month to US$172.9bn. It's noted investment gains of US$10.5bn offset net outflows of -US$3.2bn, driving overall FUM growth despite continued flow pressure.

The broker suggests recent performance improvements may signal early signs of a turnaround, though sustained flow stabilisation remains key. FY26 and FY27 EPS forecasts are raised by by 1% and 2%, respectively, on higher FUM assumptions.

Target price is $2.03 Current Price is $1.81 Difference: $0.225
If GQG meets the Morgans target it will return approximately 12% (excluding dividends, fees and charges).

Current consensus price target is $1.93, suggesting upside of 9.4% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY27:

Forecast for FY28:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates GQG as Buy (1) -

GQG Partners reported record FUM of US$172.9bn in February, rising 4.3% m/m on strong market returns despite continued net outflows of -US$3.2bn.

UBS highlights US equity flows improved as recent performance strengthened, generating around 14% alpha over the past four months, though Emerging Markets remains a headwind with outflows accelerating to a record -$1.3bn.

UBS expects March FUM to fall to around US$162bn as market declines offset positive alpha across strategies.

EPS forecasts slips by -5% for FY26 and -7% for FY27 to reflect the February update and weaker early March market performance.

Buy rated with the target price reduced to $2.00 from $2.08.

Target price is $2.00 Current Price is $1.81 Difference: $0.195
If GQG meets the UBS target it will return approximately 11% (excluding dividends, fees and charges).

Current consensus price target is $1.93, suggesting upside of 9.4% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY27:

Forecast for FY28:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Bell Potter rates LYC as Upgrade to Hold from Sell (3) -

Lynas Rare Earths has extended the Japan Australia Rare Earths agreement to 2038. The extended agreement allows for deliveries of up to 7200tpa of niobium Pr with firm commitments of 5000tpa.

While welcoming the announcement, Bell Potter continues to envisage risks around the valuation premium and multiple for the stock which is "pricing in perfection in an imperfect world".

The announcement safeguards a substantial portion of revenue and earnings and reduces the impact of adverse price swings should additional supply enter the market in coming years. The broker upgrades to Hold from Sell and raises the target to $19.00 from $11.60.

Target price is $19.00 Current Price is $20.59 Difference: minus $1.59 (current price is over target).
If LYC meets the Bell Potter target it will return approximately minus 8% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $17.23, suggesting downside of -18.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.2

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates LYC as Sell (5) -

Lynas Rare Earths has secured a revised long-term supply agreement with Japan, locking in sales of 5ktpa NdPr and half of heavy rare earth oxide output.

Ord Minnett highlights a floor price of US$110/kg for NdPr through to 2038 alongside firm offtake of 50% of heavy rare earth oxide supply for Japanese industrial consumers.

The agreement is considered strategically important as Japan secures non-China supply, while Lynas strengthens its position amid rising geopolitical competition in rare earths.

Further catalysts are anticipated from potential ore supply agreements, Malaysian magnet manufacturing expansion and US magnet supply partnerships.

Ord Minnett retains a Sell rating and $14 target for Lynas.

Target price is $14.00 Current Price is $20.59 Difference: minus $6.59 (current price is over target).
If LYC meets the Ord Minnett target it will return approximately minus 32% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $17.23, suggesting downside of -18.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.2

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates LYC as Buy (1) -

UBS argues the enhanced Lynas Rare Earths agreement with JARE marks another step in the bifurcation of Western rare earth supply chains away from China.

The broker upgrades its NdPr price forecasts by 19%–34% through 2029 and lifts the long term assumption to US$120/kg from US$100/kg, reflecting the new US$110/kg floor price under the JARE offtake agreement.

Forecast changes drive EPS upgrades of 24–49% across FY26–FY28. UBS also attributes additional valuation upside to Lynas’ downstream magnet strategy via the planned JS Link JV in Malaysia, adding about $2.80/sh to valuation.

Buy retained, target price increased to $23.90 from $17.70

Target price is $23.90 Current Price is $20.59 Difference: $3.31
If LYC meets the UBS target it will return approximately 16% (excluding dividends, fees and charges).

Current consensus price target is $17.23, suggesting downside of -18.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.2

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates OBM as Outperform (1) -

Post the significant rise in the Davyhurst mineral resource estimate to 50.3mt at 2.0g/t for 3.3moz, a rise of 57%, Macquarie lifts its outlook for Ora Banda Mining.

The analyst assumes a 3mtpa processing plant as a base case, ramping up from 3Q28 onwards versus the previous forecast of a circa 1.7mtpa run rate.

Target price is raised 13% to $1.70 with an Outperform rating retained. No change to FY26 EPS forecast, with FY27 lowered by -12% due to slightly lower production and capex for the new Davyhurst mill.

Target price is $1.70 Current Price is $1.42 Difference: $0.285
If OBM meets the Macquarie target it will return approximately 20% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Morgans rates PNR as Buy (1) -

Pantoro Gold delivered a first half result where revenue was up 56% and broadly in line with Morgans, yet production was downgraded. Updated production forecast of 86-92,000 ounces is considerably lower than expected (previously 100-110,000).

The downgrade reflects rainfall disruptions from ex Tropical Cyclone Mitchell and labour availability constraints. The broker is disappointed with the guidance downgrade while the continued sporadic production at Norseman is becoming a concern.

Recent share price weakness has reset the valuation entry point, and with gold prices elevated, the broker still assesses the leverage to spot prices is significant for an unhedged and debt-free producer.

Buy rating retained. Target is reduced to $6.53 from $6.83.

Target price is $6.53 Current Price is $3.87 Difference: $2.66
If PNR meets the Morgans target it will return approximately 69% (excluding dividends, fees and charges).

Current consensus price target is $6.56, suggesting upside of 78.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Citi rates REA as Buy (1) -

Citi points out new listings were up 1% in February after 10 months of consecutive year-on-year declines. January and February are seasonally low months with volumes starting to rise from March and peaking just before Easter.

Rate hikes may be a headwind and Citi economists expect a hike in March as well as May, largely factored into forecasts.

The two largest and highest yielding markets, Melbourne and Sydney, continue to outperform and the broker considers this positive for yield, signalling upside for REA Group's yield growth guidance. Buy rating. Target is $199.

Target price is $199.00 Current Price is $169.49 Difference: $29.51
If REA meets the Citi target it will return approximately 17% (excluding dividends, fees and charges).

Current consensus price target is $224.84, suggesting upside of 33.9% (ex-dividends)

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.9

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates S32 as Buy (1) -

UBS is more constructive on aluminium and cautious on alumina following Middle East conflict related logistics disruptions, which could threaten around 10% of global smelting capacity in the Gulf and lift aluminium premiums in the US and Europe. 

The broker expects disruptions to reduce alumina demand while tightening aluminium markets, creating favourable relative pricing for aluminium producers such as Alcoa. 

Higher gas prices following the conflict are also supporting thermal coal prices in the near term, though UBS still expects thermal coal demand to decline over the medium term with prices trending back below US$100/t. 

Metallurgical coal prices are expected to remain supported above US$200/t near term due to weather risks and Indian demand growth, with UBS forecasting about US$220/t in 2027. 

Target price on South32 raised to $5.20 from $5.10. No change to Buy rating.

Target price is $5.20 Current Price is $4.36 Difference: $0.84
If S32 meets the UBS target it will return approximately 19% (excluding dividends, fees and charges).

Current consensus price target is $5.01, suggesting upside of 15.9% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates SHL as Hold (3) -

Sonic Healthcare faces medium-term risk from potential German medical fee reforms, Ord Minnett cautions. These changes relate to the private health insurance schedule covering consultation and laboratory services.

The broker estimates laboratory fee cuts averaging around -20% under possible reforms. It's noted the fee schedule for physicians in Germany (GOA) has reimbursements representing roughly one-third of German division revenue and about 8% of group revenue.

Ord Minnett expects possible implementation from January 2028, while final legislation details may emerge after October as political approval processes progress.

The broker's profit forecast in FY29 could fall by between -4%-27% depending on the final structure, while industry consolidation may create acquisition opportunities for larger operators.

Hold rating and $24.00 target retained.

Target price is $24.00 Current Price is $21.51 Difference: $2.49
If SHL meets the Ord Minnett target it will return approximately 12% (excluding dividends, fees and charges).

Current consensus price target is $25.41, suggesting upside of 20.4% (ex-dividends)

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Ord Minnett rates SKO as Buy (1) -

Serko’s investor day highlighted strategy execution progress, Ord Minnett reports, with FY26 revenue guidance narrowed to NZ$119m-NZ$121m from NZ$115m-NZ$123m previously.

Total spend guidance also tightened to -NZ$$121m-NZ$123m from -NZ$124m-NZ$128m, implying to the broker improved cost discipline. FY30 revenue guidance remains at NZ$250m.

Management outlined a staged US growth strategy beginning with lower-complexity travel programs via Booking.com for Business before expanding into broader corporate travel segments.

The broker's earnings (EBITDA) forecasts rise following lower expected operating costs and capital expenditure, while revenue estimates remain unchanged.

Ord Minnett cuts its target price to $4.98 from $5.00 and retains a Buy rating on Serko.

Target price is $4.98 Current Price is $1.67 Difference: $3.31
If SKO meets the Ord Minnett target it will return approximately 198% (excluding dividends, fees and charges).

Current consensus price target is $4.22, suggesting upside of 147.9% (ex-dividends)

The company's fiscal year ends in March.

Forecast for FY26:

Forecast for FY27:

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates SNZ as Buy (1) -

UBS notes modest improvement in New Zealand retirement village unit pricing and sales activity, supported by improving residential market dynamics and stronger sales execution by operators.

Quarterly unit price inflation rose 0.6% across UBS Evidence Lab data, with Summerset Group up 0.7% q/q and Ryman Healthcare up 0.6%, implying y/y growth of 1.7% and 0.8% respectively.

There has also been a continued improvement in retirement village unit sales, supported by a 12% y/y increase in rolling residential sales volumes and rising housing listings, which may signal improving vendor confidence.

The broker retains a positive sector view despite recent share price weakness, which UBS attributes partly to softer housing data and concerns around potential interest rate increases.

 Buy rating unchanged, target set at NZ$15.00.

Current Price is $8.50. Target price not assessed.

Current consensus price target is N/A

Forecast for FY26:

Forecast for FY27:

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Bell Potter rates TLX as Buy (1) -

Telix Pharmaceuticals has published safety and dosimetric data from part 1 of the ProstACT global study. The trial is targeting men with mCRPC where the primary endpoint is progression free survival.

Bell Potter notes the good news is there were no new safety signs and specific issues appear manageable.  The full data package will be discussed with the US FDA in coming weeks.

The broker expects the FDA will take a neutral view on the data and allow part 2 to commence recruitment. Buy rating and $19 target maintained.

Target price is $19.00 Current Price is $10.76 Difference: $8.24
If TLX meets the Bell Potter target it will return approximately 77% (excluding dividends, fees and charges).

Current consensus price target is $25.84, suggesting upside of 130.1% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY26:

Forecast for FY27:

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Macquarie rates VGL as Neutral (3) -

Vista International's direct sites fell -2.9% for the year to December 2025, and management places global market share (ex RIC), Macquarie explains, at 46% over that period.

The analyst estimates North American box office attendance declined by -3% y/y and drops its 100% platform site assumption by -7% to 4,614, a 3% rise on 2025 for some market share gain but below Vista's target of 6,000 sites.

Maintenance output is now assumed at 2.4x, real from FY29, against 3.0x previously.

Neutral rating unchanged. Target downgraded to NZ$1.82 from NZ$3.20, with EPS forecasts cut by -19% and -39% for FY26/FY27, respectively, on lower platform site and maintenance outputs.

Current Price is $1.50. Target price not assessed.

Current consensus price target is $3.22, suggesting upside of 107.7% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY26:

Forecast for FY27:

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

UBS rates WHC as Sell (5) -

UBS is more constructive on aluminium and cautious on alumina following Middle East conflict related logistics disruptions, which could threaten around 10% of global smelting capacity in the Gulf and lift aluminium premiums in the US and Europe. 

The broker expects disruptions to reduce alumina demand while tightening aluminium markets, creating favourable relative pricing for aluminium producers such as Alcoa. 

Higher gas prices following the conflict are also supporting thermal coal prices in the near term, though UBS still expects thermal coal demand to decline over the medium term with prices trending back below US$100/t. 

Metallurgical coal prices are expected to remain supported above US$200/t near term due to weather risks and Indian demand growth, with UBS forecasting about US$220/t in 2027. 

Sell rating retained for Whitehaven Coal with a lift in target to $7.90 from $7.70.

Target price is $7.90 Current Price is $8.71 Difference: minus $0.81 (current price is over target).
If WHC meets the UBS target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $8.78, suggesting downside of -5.5% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY26:

Forecast for FY27:

Market Sentiment: 0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources